BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 25962426)

  • 1. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.
    Yeo W; Chan SL; Mo FK; Chu CM; Hui JW; Tong JH; Chan AW; Koh J; Hui EP; Loong H; Lee K; Li L; Ma B; To KF; Yu SC
    BMC Cancer; 2015 May; 15():395. PubMed ID: 25962426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
    Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
    Yeo W; Chung HC; Chan SL; Wang LZ; Lim R; Picus J; Boyer M; Mo FK; Koh J; Rha SY; Hui EP; Jeung HC; Roh JK; Yu SC; To KF; Tao Q; Ma BB; Chan AW; Tong JH; Erlichman C; Chan AT; Goh BC
    J Clin Oncol; 2012 Sep; 30(27):3361-7. PubMed ID: 22915658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
    McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
    Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chen CY; Dai CY; Hsiao CF; Lin YJ; Su WC; Chang JY; Whang-Peng J; Lin PW; Huang JD; Chen LT
    Aliment Pharmacol Ther; 2013 Jan; 37(1):62-73. PubMed ID: 23134470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
    Faivre S; Raymond E; Boucher E; Douillard J; Lim HY; Kim JS; Zappa M; Lanzalone S; Lin X; Deprimo S; Harmon C; Ruiz-Garcia A; Lechuga MJ; Cheng AL
    Lancet Oncol; 2009 Aug; 10(8):794-800. PubMed ID: 19586800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.
    Schnitzbauer AA; Zuelke C; Graeb C; Rochon J; Bilbao I; Burra P; de Jong KP; Duvoux C; Kneteman NM; Adam R; Bechstein WO; Becker T; Beckebaum S; Chazouillères O; Cillo U; Colledan M; Fändrich F; Gugenheim J; Hauss JP; Heise M; Hidalgo E; Jamieson N; Königsrainer A; Lamby PE; Lerut JP; Mäkisalo H; Margreiter R; Mazzaferro V; Mutzbauer I; Otto G; Pageaux GP; Pinna AD; Pirenne J; Rizell M; Rossi G; Rostaing L; Roy A; Turrion VS; Schmidt J; Troisi RI; van Hoek B; Valente U; Wolf P; Wolters H; Mirza DF; Scholz T; Steininger R; Soderdahl G; Strasser SI; Jauch KW; Neuhaus P; Schlitt HJ; Geissler EK
    BMC Cancer; 2010 May; 10():190. PubMed ID: 20459775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study.
    Karavasilis V; Samantas E; Koliou GA; Kalogera-Fountzila A; Pentheroudakis G; Varthalitis I; Linardou H; Rallis G; Skondra M; Papadopoulos G; Papatsibas G; Sgouros J; Goudopoulou A; Kalogeras KT; Dervenis C; Pectasides D; Fountzilas G
    Target Oncol; 2018 Dec; 13(6):715-724. PubMed ID: 30488350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
    Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.
    Decaens T; Luciani A; Itti E; Hulin A; Roudot-Thoraval F; Laurent A; Zafrani ES; Mallat A; Duvoux C
    Dig Liver Dis; 2012 Jul; 44(7):610-6. PubMed ID: 22459565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Choi C; Koom WS; Kim TH; Yoon SM; Kim JH; Lee HS; Nam TK; Seong J
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1051-60. PubMed ID: 25303890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
    Zhu AX; Stuart K; Blaszkowsky LS; Muzikansky A; Reitberg DP; Clark JW; Enzinger PC; Bhargava P; Meyerhardt JA; Horgan K; Fuchs CS; Ryan DP
    Cancer; 2007 Aug; 110(3):581-9. PubMed ID: 17583545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial.
    Yang KL; Chi MS; Ko HL; Huang YY; Huang SC; Lin YM; Chi KH
    Radiat Oncol; 2021 Jan; 16(1):18. PubMed ID: 33472666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
    Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG
    Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
    Behbakht K; Sill MW; Darcy KM; Rubin SC; Mannel RS; Waggoner S; Schilder RJ; Cai KQ; Godwin AK; Alpaugh RK
    Gynecol Oncol; 2011 Oct; 123(1):19-26. PubMed ID: 21752435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
    Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
    J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).
    Tinker AV; Ellard S; Welch S; Moens F; Allo G; Tsao MS; Squire J; Tu D; Eisenhauer EA; MacKay H
    Gynecol Oncol; 2013 Aug; 130(2):269-74. PubMed ID: 23672928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.